109 related articles for article (PubMed ID: 38789608)
1. Ozempic keeps wowing: trial data show benefits for kidney disease.
Fairbank R
Nature; 2024 Jun; 630(8015):16-17. PubMed ID: 38789608
[No Abstract] [Full Text] [Related]
2. Oral semaglutide (Rybelsus) for type 2 diabetes.
Med Lett Drugs Ther; 2019 Oct; 61(1583):166-168. PubMed ID: 31770356
[No Abstract] [Full Text] [Related]
3. Diabetes: Cardiovascular benefits of semaglutide.
Lim GB
Nat Rev Cardiol; 2016 Dec; 13(12):697. PubMed ID: 27708277
[No Abstract] [Full Text] [Related]
4. Semaglutide, a newly available glucagon-like peptide receptor agonist, shows remarkable favorable effects in hemodialysis patients with obesity and Type 2 diabetes.
Saito S; Nakao T
Ther Apher Dial; 2022 Feb; 26(1):242-243. PubMed ID: 33830659
[No Abstract] [Full Text] [Related]
5. SCORED and SOLOIST: the next scores for SGLT2 inhibitors.
Bauersachs J
Cardiovasc Res; 2021 Mar; 117(4):e49-e51. PubMed ID: 33439963
[No Abstract] [Full Text] [Related]
6. [Semaglutide, once weekly GLP-1 receptor agonist (Ozempic®)].
Scheen AJ
Rev Med Liege; 2019 Sep; 74(9):488-494. PubMed ID: 31486321
[TBL] [Abstract][Full Text] [Related]
7. Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Systematic Literature Review.
Feier CVI; Vonica RC; Faur AM; Streinu DR; Muntean C
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673931
[TBL] [Abstract][Full Text] [Related]
8. Semaglutide: First Global Approval.
Dhillon S
Drugs; 2018 Feb; 78(2):275-284. PubMed ID: 29363040
[TBL] [Abstract][Full Text] [Related]
9. Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity.
Newsome P; Francque S; Harrison S; Ratziu V; Van Gaal L; Calanna S; Hansen M; Linder M; Sanyal A
Aliment Pharmacol Ther; 2019 Jul; 50(2):193-203. PubMed ID: 31246368
[TBL] [Abstract][Full Text] [Related]
10. Semaglutide (Ozempic) for Type 2 Diabetes Mellitus.
Chamberlin S; Dabbs W
Am Fam Physician; 2019 Jul; 100(2):116-117. PubMed ID: 31305048
[No Abstract] [Full Text] [Related]
11. Management of patients with type 2 diabetes mellitus and acute coronary syndrome: Better be safe than sorry!
Katsiki N; Mikhailidis DP
J Diabetes Complications; 2019 Jul; 33(7):465-467. PubMed ID: 31126705
[No Abstract] [Full Text] [Related]
12. Effect of Glucagon-like Peptide-1 Receptor Agonists on All-cause Mortality and Cardiovascular Outcomes: A Meta-analysis.
Peterson SC; Barry AR
Curr Diabetes Rev; 2018; 14(3):273-279. PubMed ID: 28413990
[TBL] [Abstract][Full Text] [Related]
13. Semaglutide (Ozempic) for weight loss.
Med Lett Drugs Ther; 2021 Apr; 63(1621):53-54. PubMed ID: 33830968
[No Abstract] [Full Text] [Related]
14. Role of glucagon-like peptide 1 receptor agonists in management of obesity.
Isaacs D; Prasad-Reddy L; Srivastava SB
Am J Health Syst Pharm; 2016 Oct; 73(19):1493-507. PubMed ID: 27521241
[TBL] [Abstract][Full Text] [Related]
15. Comment on: Semaglutide and cardiovascular outcomes in obesity without diabetes.
Basolo A; Fierabracci P; Salvetti G; Santini F
J Endocrinol Invest; 2024 May; 47(5):1047-1049. PubMed ID: 38157134
[No Abstract] [Full Text] [Related]
16. In brief: Higher-dose semaglutide (Ozempic) for type 2 diabetes.
Med Lett Drugs Ther; 2022 May; 64(1650):79. PubMed ID: 35536124
[No Abstract] [Full Text] [Related]
17. Semaglutide and Cardiovascular Outcomes.
Neves JS; Leite AR; Ferreira JP
N Engl J Med; 2024 Feb; 390(8):767-768. PubMed ID: 38381686
[No Abstract] [Full Text] [Related]
18. Semaglutide and Cardiovascular Outcomes.
Campbell LA; Jenkins AV; Jackson CD
N Engl J Med; 2024 Feb; 390(8):767. PubMed ID: 38381685
[No Abstract] [Full Text] [Related]
19. Semaglutide and Cardiovascular Outcomes.
Belkhouribchia J
N Engl J Med; 2024 Feb; 390(8):767. PubMed ID: 38381684
[No Abstract] [Full Text] [Related]
20. Semaglutide and Cardiovascular Outcomes.
Belalcazar LM; Kuo YF
N Engl J Med; 2024 Feb; 390(8):766-767. PubMed ID: 38381683
[No Abstract] [Full Text] [Related]
[Next] [New Search]
